Brief: Orchard Announces Additional Interim Results From Proof-Of-Concept Study Of OTL-203 For MPS-I
01/09/2020 12:34
Sept 1 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS PLC - ANNOUNCES ADDITIONAL INTERIM
RESULTS
FROM PROOF-OF-CONCEPT STUDY OF OTL-203 FOR MPS-I
* ORCHARD THERAPEUTICS PLC - DATA ON ALL EIGHT PATIENTS
DEMONSTRATE SUSTAINED ENGRAFTMENT AND SUPRANORMAL IDUA ENZYME
EXPRESSION
* ORCHARD THERAPEUTICS PLC - DATA SUPPORT PLANNED INITIATION
OF
REGISTRATIONAL TRIAL IN 2021
Source text for Eikon: ID:nGNX6pWJ3r
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln